Table 5.
Pemetrexed-based therapies impact on survival based on NSCLC histologic subtype
| Trial | Treatment groups | Histologic subtype | Number of patients | Median survival (months) | Hazard ratio for A vs B (95% CI) | |
|---|---|---|---|---|---|---|
| Peterson65 | Pemetrexed (A) vs docetaxel (B) | Adenocarcinoma | A | 158 | 9.0 | 0.915 (0.685 to 1.224) |
| B | 144 | 9.2 | ||||
| Large cell | A | 18 | 12.8 | 0.266 (0.112–0.633) | ||
| B | 29 | 4.5 | ||||
| Squamous cell | A | 78 | 6.2 | 1.563 (1.079 to 2.264) | ||
| B | 94 | 7.4 | ||||
| All nonsquamous | A | 205 | 9.3 | 0.778 (0.607 to 0.997) | ||
| B | 194 | 8.0 | ||||
| Median survival (months) | Hazard ratio for A vs B (95% CI) | |||||
| Scagliotti66,67 | Pemetrexed + cisplatin (A) vs cisplatin + gemcitabine (B) | Adenocarcinoma | A | 847 | 12.6 | 0.84 (0.71 to 0.99) |
| B | 10.9 | |||||
| Large cell | A | 153 | 10.4 | 0.67 (0.48 to 0.96) | ||
| B | 6.7 | |||||
| Squamous cell | A | 473 | 9.4 | 1.23 (1.00 to 1.51) | ||
| B | 10.8 | |||||
| All nonsquamous | A | 1000 | 11.8 | 0.81 (0.70 to 0.94) | ||
| B | 10.4 | |||||
| Median survival (months) | Hazard ratio for A vs B (95% CI) | |||||
| Peng68 | Pemetrexed + carboplatin or oxaliplatin in nonsquamous (A) vs squamous (B) | Nonsquamous | A | 100 | 10.5 | 0.95 (0.52 to 1.74) |
| Squamous | B | 29 | 9.8 | |||
| Objective tumor response (CR + PR + SD) | P value | |||||
| Ciuleanu69 | Pemetrexed (A) vs BSC (B) | Adenocarcinoma | A | 329 | 61.0% | |
| B | 33.0% | <0.001 | ||||
| Large cell | A | 20 | 45.5 % | |||
| B | 33.3% | 0.670 | ||||
| Squamous cell | A | 181 | 34.8% | |||
| B | 34.8% | 1.000 | ||||
| All nonsquamous | A | 482 | 51.7% | |||
| B | 33.3% | <0.001 |
Abbreviations: BSC, best supportive care; CR, complete response; PR, partial response; SD, stable disease.